Benzinga · Nov 11, 2026
Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $96
Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $120 to $96.
GO
NASDAQ · GOSS
Gossamer Bio, Inc.
Healthcare · Biotechnology
$11.24
Down-$0.45 (-3.85%)
Updated Nov 13, 2026, 11:27 AM
SID Score
6.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 824.25M
- P/E ratio
- -5.95
- Dividend yield
- 0.00%
- 52-week range
- $0.11 – $14.75
- Volume
- 189K
- Avg. volume
- 3.24M
Price performance · GOSS
GOSS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 12, 2026
GOSS closed at $11.24 after 21 trading sessions, up 26.43% for the selected period.
- Last close
- $11.24
- Period change
- +26.43%
- Period low
- $8.43
- Period high
- $11.69
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | $11.27 | $12.15 | $10.60 | $11.24 | 189K |
| Nov 11, 2026 | $9.76 | $11.94 | $9.71 | $11.69 | 335.92K |
| Nov 10, 2026 | $10.52 | $11.535 | $10.42 | $11.28 | 100.31K |
| Nov 9, 2026 | $9.93 | $11.58 | $9.545 | $10.645 | 234.67K |
| Nov 6, 2026 | $9.27 | $9.99 | $9.27 | $9.77 | 84.73K |
| Nov 5, 2026 | $9.77 | $9.77 | $8.91 | $9.42 | 151.77K |
| Nov 4, 2026 | $9.42 | $10.04 | $9.42 | $9.95 | 115.91K |
| Nov 3, 2026 | $9.38 | $9.68 | $8.80 | $9.28 | 139.44K |
| Nov 2, 2026 | $10.30 | $10.35 | $9.30 | $9.45 | 190.79K |
| Oct 30, 2026 | $10.56 | $10.75 | $10.17 | $10.38 | 179.49K |
| Oct 29, 2026 | $10.70 | $11.08 | $10.4785 | $10.69 | 108.75K |
| Oct 28, 2026 | $9.61 | $10.8763 | $9.45 | $10.69 | 186.04K |
| Oct 27, 2026 | $9.17 | $9.87 | $9.10 | $9.77 | 138.04K |
| Oct 26, 2026 | $9.61 | $9.644 | $8.68 | $9.15 | 250.87K |
| Oct 23, 2026 | $9.40 | $9.77 | $9.00 | $9.605 | 144.83K |
| Oct 22, 2026 | $9.73 | $9.965 | $9.34 | $9.46 | 190.61K |
| Oct 21, 2026 | $9.50 | $10.39 | $9.50 | $9.79 | 218.98K |
| Oct 20, 2026 | $8.41 | $9.625 | $8.29 | $9.58 | 214.55K |
| Oct 19, 2026 | $8.80 | $8.885 | $8.3105 | $8.43 | 181.02K |
| Oct 16, 2026 | $8.88 | $8.995 | $8.5101 | $8.77 | 171.14K |
| Oct 15, 2026 | $8.86 | $9.18 | $8.73 | $8.89 | 197.8K |
Latest GOSS news
The latest Smart Investors Daily articles mentioning GOSS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GOSS research
Overview
Company profile and research snapshot.
Company profile
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $9.00
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 11, 2026 | Piper Sandler | Overweight | — |
| Nov 11, 2026 | Wedbush | Neutral | — |
| Oct 26, 2026 | Chardan Capital | Buy | — |
| Oct 15, 2026 | Chardan Capital | Buy | — |
| Oct 13, 2026 | Chardan Capital | Buy | — |
News briefing
Generated Nov 13, 2026, 11:24 AM
Why Is GOSS Down Today?
Gossamer Bio shares fell 3.85% today amid mixed Q3 earnings results and divergent analyst perspectives on the company's valuation. While the biotech firm beat revenue expectations significantly, it missed on earnings per share, triggering a reassessment from multiple analyst firms with conflicting outlooks.
Bottom line: Gossamer Bio presents a classic growth-at-a-cost story: strong revenue momentum undermined by near-term profitability challenges and analyst confusion about proper valuation. The wide spread between bullish and bearish analyst targets suggests investors should await clearer signals on operating leverage improvements before taking a conviction stance, while monitoring upcoming quarters for evidence that top-line growth is translating to bottom-line improvement.
Benzinga · Nov 11, 2026
Wedbush Maintains Neutral on Gossamer Bio, Lowers Price Target to $32
Wedbush analyst Laura Chico maintains Gossamer Bio (NASDAQ:GOSS) with a Neutral and lowers the price target from $80 to $32.
Yahoo · Nov 10, 2026
Gossamer Bio: Q3 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Gossamer Bio Inc. (GOSS) on Tuesday reported a loss of $48.
Yahoo · Nov 10, 2026
Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, November 10, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
